A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a Phase 1b, multicenter, randomized, placebo‐controlled, double‐blind, multipleascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD),defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloidpositivity.Note: In the Netherlands, this study includes an open‐label extension.
Epistemonikos ID: 8f032b0206bebcb876cf72e9d5f2939e35a782e5
First added on: Jan 10, 2026